At a glance
- Originator Sofotec
- Developer AEterna Zentaris GmbH; Sofotec
- Class Infertility therapies; Peptides
- Mechanism of Action Gonadotropin releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Benign prostatic hyperplasia
Most Recent Events
- 01 Aug 2006 No development reported for Benign prostatic hyperplasia in Germany (Inhalation)
- 01 Jun 2004 AEterna Laboratories is now called AEterna Zentaris
- 30 Dec 2002 Zentaris has been acquired by AEterna Laboratories